Literature DB >> 33149023

Differential Expression of PEG10 Contributes to Aggressive Disease in Early Versus Late-Onset Colorectal Cancer.

Katherine M Watson1, Ivy H Gardner1, Raphael M Byrne1, Rebecca R Ruhl2, Christian P Lanciault3, Elizabeth N Dewey1, Sudarshan Anand4,5, Vassiliki Liana Tsikitis1.   

Abstract

BACKGROUND: Colorectal cancer is a leading cause of cancer-related death. Early onset colorectal cancer (age ≤45 y) is increasing and associated with advanced disease. Although distinct molecular subtypes of colorectal cancer have been characterized, it is unclear whether age-related molecular differences exist.
OBJECTIVE: We sought to identify differences in gene expression between early and late-onset (age ≥65 y) colorectal cancer.
DESIGN: We performed a review of our institution's colorectal cancer registry and identified patients with colorectal cancer with tissue specimens available for analysis. We used the Cancer Genome Atlas to initially identify differences in gene expression between early and late-onset colorectal cancer. In vitro experiments were performed on 2 colorectal cancer cell lines. SETTINGS: The study was conducted at a tertiary medical center. PATIENTS: Patients with early onset (n = 28) or late onset (age ≥65 y; n = 38) at time of diagnosis were included. MAIN OUTCOME MEASURES: The primary outcome was differential gene expression in patients with early versus late-onset colorectal cancer. The secondary outcome was patient mortality.
RESULTS: Seven genes had increased expression in younger patients using The Cancer Genome Atlas. Only PEG10 was sufficiently expressed with quantitative polymerase chain reaction and had increased expression in our early onset group. Multivariable linear regression analysis identified age as a significant independent predictor of increased PEG10 expression. Outcomes data from The Cancer Genome Atlas suggests that PEG10 is associated with poor overall survival. In vitro studies in HCT-116 and HT-29 cell lines showed that PEG10 contributes to cellular proliferation and invasion in colorectal cancer. LIMITATIONS: Tissue samples were from formalin-fixed, paraffin-embedded sections. Many patients did not have mutational status for review.
CONCLUSIONS: PEG10 is differentially expressed in early onset colorectal cancer and may functionally contribute to tumor cell proliferation and invasion. An increase in PEG10 expression correlates with decreased overall survival. See Video Abstract at http://links.lww.com/DCR/B343. LA EXPRESIÓN DIFERENCIAL DE PEG10 CONTRIBUYE A LA ENFERMEDAD AGRESIVA EN EL CÁNCER COLORRECTAL DE INICIO TEMPRANO VERSUS INICIO TARDÍO: El cáncer colorrectal es una de las principales causas de muerte relacionada con el cáncer. El cáncer colorrectal de inicio temprano (edad ≤45 años) está en aumento y asociado con enfermedad avanzada. Aunque se han caracterizado distintos subtipos moleculares del cáncer colorrectal, no está claro si existen diferencias moleculares relacionadas con la edad.Se buscó identificar diferencias en la expresión génica entre el cáncer colorrectal de inicio temprano y tardío (edad ≥ 65 años).Realizamos una revisión del registro de cáncer colorrectal de nuestra institución e identificamos pacientes con cáncer colorrectal con muestras de tejido disponibles para su análisis. Utilizamos el Atlas del Genoma del Cáncer para identificar inicialmente las diferencias en la expresión génica entre el cáncer colorrectal de inicio temprano y de inicio tardío. Se realizaron experimentos in vitro en dos líneas celulares de cáncer colorrectal.El estudio se realizó en un centro médico de tercer nivel.Se incluyeron pacientes con inicio temprano (n = 28) e inicio tardío (edad ≥65 años, n = 38) al momento del diagnóstico.El resultado primario fue la expresión diferencial de genes en pacientes con cáncer colorrectal de inicio temprano versus tardío. El resultado secundario fue la mortalidad de los pacientes.Siete genes aumentaron su expresión en pacientes más jóvenes usando el Atlas del Genoma del Cáncer. Solo PEG10 se expresó suficientemente con la reacción en cadena de la polimerasa cuantitativa y tuvo una mayor expresión en nuestro grupo de inicio temprano. El análisis de regresión lineal multivariable identificó la edad como un predictor independiente significativo del aumento de la expresión de PEG10. Los datos de resultados de el Atlas del Genoma del Cáncer sugieren que PEG10 está asociado con una pobre supervivencia general. Los estudios in vitro en líneas celulares HCT-116 y HT-29 mostraron que PEG10 contribuye a la proliferación e invasión celular en el cáncer colorrectal.Las muestras de tejido fueron de portaobjetos embebidos en parafina fijados con formalina. Muchos pacientes no tenían el estado de mutación para su revisión.El PEG10 se expresa diferencialmente en el cáncer colorrectal de inicio temprano y puede contribuir funcionalmente a la proliferación e invasión de células tumorales. El aumento en la expresión de PEG10 se correlaciona con la disminución de la supervivencia general. Consulte Video Resumen en http://links.lww.com/DCR/B343.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33149023      PMCID: PMC7653836          DOI: 10.1097/DCR.0000000000001774

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.412


  29 in total

1.  Are survival rates different for young and older patients with rectal cancer?

Authors:  Jessica B O'Connell; Melinda A Maggard; Jerome H Liu; David A Etzioni; Clifford Y Ko
Journal:  Dis Colon Rectum       Date:  2004-12       Impact factor: 4.585

2.  NIH Image to ImageJ: 25 years of image analysis.

Authors:  Caroline A Schneider; Wayne S Rasband; Kevin W Eliceiri
Journal:  Nat Methods       Date:  2012-07       Impact factor: 28.547

3.  Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010.

Authors:  Christina E Bailey; Chung-Yuan Hu; Y Nancy You; Brian K Bednarski; Miguel A Rodriguez-Bigas; John M Skibber; Scott B Cantor; George J Chang
Journal:  JAMA Surg       Date:  2015-01       Impact factor: 14.766

4.  PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia.

Authors:  Chunsong Hu; Jei Xiong; Linjei Zhang; Baojun Huang; Qiuping Zhang; Qun Li; Mingzhen Yang; Yaou Wu; Qun Wu; Qian Shen; Qingping Gao; Kejian Zhang; Zhimin Sun; Junyan Liu; Youxin Jin; Jinquan Tan
Journal:  Cell Mol Immunol       Date:  2004-08       Impact factor: 11.530

5.  Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1.

Authors:  Hiroshi Okabe; Seiji Satoh; Yoichi Furukawa; Tatsushi Kato; Suguru Hasegawa; Yumi Nakajima; Yoshio Yamaoka; Yusuke Nakamura
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

Review 6.  Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features.

Authors:  Giulia Martina Cavestro; Alessandro Mannucci; Raffaella Alessia Zuppardo; Milena Di Leo; Elena Stoffel; Giovanni Tonon
Journal:  Dig Liver Dis       Date:  2018-02-23       Impact factor: 4.088

7.  PEG10 plays a crucial role in human lung cancer proliferation, progression, prognosis and metastasis.

Authors:  Xinzhou Deng; Yi Hu; Qianshan Ding; Rongfei Han; Qian Guo; Jian Qin; Jie Li; Ruijing Xiao; Sufang Tian; Weidong Hu; Qiuping Zhang; Jie Xiong
Journal:  Oncol Rep       Date:  2014-09-09       Impact factor: 3.906

8.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

9.  PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer.

Authors:  Yun-Peng Peng; Yi Zhu; Ling-Di Yin; Jing-Jing Zhang; Ji-Shu Wei; Xian Liu; Xin-Chun Liu; Wen-Tao Gao; Kui-Rong Jiang; Yi Miao
Journal:  J Exp Clin Cancer Res       Date:  2017-02-13

10.  Epigenetic and genetic features of 24 colon cancer cell lines.

Authors:  D Ahmed; P W Eide; I A Eilertsen; S A Danielsen; M Eknæs; M Hektoen; G E Lind; R A Lothe
Journal:  Oncogenesis       Date:  2013-09-16       Impact factor: 7.485

View more
  4 in total

1.  Survival stratification for colorectal cancer via multi-omics integration using an autoencoder-based model.

Authors:  Hu Song; Chengwei Ruan; Yixin Xu; Teng Xu; Ruizhi Fan; Tao Jiang; Meng Cao; Jun Song
Journal:  Exp Biol Med (Maywood)       Date:  2021-12-14

2.  ISLR affects colon cancer progression by regulating the epithelial-mesenchymal transition signaling pathway.

Authors:  Chunhua Chi; Tongming Liu; Shengnan Yang; Benjun Wang; Weiwei Han; Jiansheng Li
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

3.  Structural evidence that MOAP1 and PEG10 are derived from retrovirus/retrotransposon Gag proteins.

Authors:  Katarzyna Zurowska; Ayaan Alam; Barbie K Ganser-Pornillos; Owen Pornillos
Journal:  Proteins       Date:  2021-08-21

4.  A Distinct Innate Immune Signature of Early Onset Colorectal Cancer.

Authors:  Ivy H Gardner; Ragavan Siddharthan; Katherine Watson; Elizabeth Dewey; Rebecca Ruhl; Sokchea Khou; Xiangnan Guan; Zheng Xia; V Liana Tsikitis; Sudarshan Anand
Journal:  Immunohorizons       Date:  2021-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.